(Q86328482)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23474348%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

title

Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23474348%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

1 reference

1 reference

1 reference

1 reference

Deborah K Armstrong

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23474348%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Allen J White

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23474348%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Susan C Weil

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23474348%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Martin Phillips

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23474348%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Robert L Coleman

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23474348%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

publication date

6 March 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23474348%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23474348%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

volume

129

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23474348%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23474348%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

page(s)

452-458

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23474348%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.002

Improved survival time: what can survival cure models tell us about population-based survival improvements in late-stage colorectal, ovarian, and testicular cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.002

A step further in understanding the biology of the folate receptor in ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.002

Overexpression of folate binding protein in ovarian cancers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.002

Farletuzumab, an anti-folate receptor α antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.002

Farletuzumab in epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.002

Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.002

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.002

Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.002

Use of CA-125 to Assess Response to New Agents in Ovarian Cancer Trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.002

Toxicity and response criteria of the Eastern Cooperative Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.002

Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.002

CA125 response: can it replace the traditional response criteria in ovarian cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.002

Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.002

Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.002

Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.002

Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.002

THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.002

Nonparametric Estimation from Incomplete Observations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.002

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.002

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.002

Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.002

Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.002

Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.002

Angiogenesis inhibitors: current strategies and future prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.002

10.1016/J.YGYNO.2013.03.002

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23474348%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

1 reference